Gene Therapy Pricing: The Economics of Million-Dollar Cures
Updated April 2026: Million-dollar gene therapy pricing analysis covering Casgevy, Lyfgenia, Lenmeldy, Elevidys (with 2025 safety update), the Roctavian and Beqvez market withdrawals, and CMS's 2025 Cell and Gene Therapy Access Model. Compares one-time cure costs to lifetime chronic care using value-based pricing, ICER QALY thresholds, and outcomes-based contracts.